{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:55:16Z","timestamp":1780764916756,"version":"3.54.1"},"reference-count":20,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2025.12819","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T13:39:26Z","timestamp":1738935566000},"source":"Crossref","is-referenced-by-count":5,"title":["Effect of dasatinib on blood concentrations of sunitinib and adverse events in a patient with metastatic renal cell carcinoma treated with sunitinib: A case report"],"prefix":"10.3892","volume":"29","author":[{"given":"Miki","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Gunma University Hospital, Maebashi, Gunma 371\u20118511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yashima","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, Gunma 371\u20118511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gunma University Hospital, Maebashi, Gunma 371\u20118511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371\u20118511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371\u20118511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koujirou","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gunma University Hospital, Maebashi, Gunma 371\u20118511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"key20250401110503_b1-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"key20250401110503_b2-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"key20250401110503_b3-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clgc.2015.01.007","article-title":"Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma","volume":"13","author":"Noda","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"key20250401110503_b4-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"25277","DOI":"10.18632\/oncotarget.25423","article-title":"Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients","volume":"9","author":"Numakura","year":"2018","journal-title":"Oncotarget"},{"key":"key20250401110503_b5-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s10147-018-1302-7","article-title":"Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma","volume":"23","author":"Takasaki","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"key20250401110503_b6-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20250401110503_b7-ETM-29-4-12819","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20250401110503_b8-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"issue":"109426","key":"key20250401110503_b9-ETM-29-4-12819","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109426","article-title":"Effects of CYP3A inhibitors ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of sunitinib and its main metabolite in rats","volume":"338","author":"Wang","year":"2021","journal-title":"Chem Biol Interact"},{"key":"key20250401110503_b10-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1124\/dmd.114.057695","article-title":"In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors","volume":"42","author":"Filppula","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"key20250401110503_b11-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1124\/dmd.108.025932","article-title":"Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways","volume":"37","author":"Li","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"key20250401110503_b12-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/0091270009333854","article-title":"Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects","volume":"49","author":"Eley","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"key20250401110503_b13-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1208\/s12248-014-9673-9","article-title":"The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria","volume":"16","author":"Yago","year":"2014","journal-title":"AAPS J"},{"key":"key20250401110503_b14-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00280-011-1797-3","article-title":"Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients","volume":"69","author":"Takahashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20250401110503_b15-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1038\/s41375-023-02045-1","article-title":"Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans","volume":"37","author":"Hofmann","year":"2023","journal-title":"Leukemia"},{"key":"key20250401110503_b16-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"key20250401110503_b17-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncol"},{"key":"key20250401110503_b18-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy","volume":"15","author":"Azad","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20250401110503_b19-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3892\/etm.2017.4133","article-title":"Role of stem cell growth factor\/c-Kit in the pathogenesis of irritable bowel syndrome","volume":"13","author":"Chai","year":"2017","journal-title":"Exp Ther Med"},{"key":"key20250401110503_b20-ETM-29-4-12819","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1078155210382060","article-title":"Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukemia-easier said than done? A case report","volume":"17","author":"Al-Najjar","year":"2011","journal-title":"J Oncol Pharm Pract"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:34:00Z","timestamp":1743496440000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2025.12819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,7]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2025.12819","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"article-number":"69"}}